Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2010

Formatech to Fill and Finish One Lot of ViroMed’s Preclinical Cancer Vaccine at No Charge

  • Formatech selected ViroMed’s VM206 therapeutic cancer vaccine as the next candidate for its Fillanthropy Program. Under this initiative, Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials. Formatech plans to complete the production run in March. 

    “VM206 is a plasmid DNA vaccine that targets HER2/neu positive breast cancer,” explains Jeffrey Bernard, Formatech’s director of business development. “Animal studies have demonstrated the vaccine’s ability to eliminate tumors and to prevent relapse and metastases. We are hopeful and optimistic that VM206 will prove to be effective in human trials.”

    Formatech set up the Fillanthropy Program to donate the services required to aseptically fill and finish one lot of selected therapeutic candidates that are entering clinical trials. The company will donate services to a new recipient each month. To be eligible companies must be developing a compound that is delivered as a sterile injectable product. 

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »